Genetic and Signaling Pathways in Epithelial Thyroid Cancer

上皮性甲状腺癌的遗传和信号通路

基本信息

批准号：
8145140
负责人：
Matthew D Ringel
金额：
$ 13.14万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-03-01 至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8145140
关键词：
17-(Allylamino)-17-demethoxygeldanamycin 1q41 4q32 8q24 Accounting Address Adopted Advanced Malignant Neoplasm Affect Age Alleles Animal Model Animals Apoptosis Area Autopsy BRAF gene Benign Biochemical Biological Markers Biological Models Bioluminescence Biopsy Blinded Breeding Calibration Cancer Control Cancer Family Cancer Model Cancer cell line Candidate Disease Gene Caregivers Case-Control Studies Cell Cycle Cell Survival Cell surface Cells Childhood Clinic Clinical Clinical Data Clinical Pathology Clinical Research Clinical Trials Code Complex Computer software Constitutional Consultations Control Groups Copy Number Polymorphism Data Databases Death Certificates Death Rate Deletion Mutation Development Diagnosis Dimethyl Sulfoxide Discrimination Disease Disease Progression Doxycycline Early Diagnosis Endocrine Environment Epithelial Event Exons Expressed Sequence Tags Family Family member Fine needle aspiration biopsy Follicular thyroid carcinoma Frequencies Functional RNA Functional disorder Gene Combinations Gene Expression Gene Mutation Generations Genes Genetic Genetic Polymorphism Genetic screening method Genome Stability Genomic Instability Germ-Line Mutation Glycine decarboxylase Goals Haplotypes Human Human Genetics Hyperplasia Image In Vitro Incidence Individual Inherited Interest Group International Investigation Iodine Kinesis Knock-out Knockout Mice Knowledge Laboratories Left Life Literature Logistic Regressions Loss of Heterozygosity Luciferases Maintenance Malignant - descriptor Malignant Neoplasms Malignant neoplasm of thyroid Mediating Mesenchymal Messenger RNA Methodology Methods Microsatellite Repeats Mining Modeling Molecular Molecular Abnormality Molecular Target Monitor Multiple Hamartoma Syndrome Mus Mutation Mutation Analysis National Comprehensive Cancer Network Neoplasms Oncogenes Other Genetics Outcome PTEN gene Papillary thyroid carcinoma Pathogenesis Pathology Pathology Report Pathway interactions Patients Pattern Penetrance Pharmaceutical Preparations Phenotype Phosphorylation Phosphorylation Site Physiological Play Poland Predisposition Prevention Primary Neoplasm Probability Procedures Process Professional counselor Progressive Disease Proteins Proteomics Public Health Publications Questionnaires RET/H4 Oncogene RNA ROC Curve Radiation Radioisotopes Reagent Recruitment Activity Relative (related person)Research Research Personnel Resources Role SAGE Library Scheme Sensitivity and Specificity Services Signal Pathway Signal Transduction Sirolimus Site-Directed Mutagenesis Staging Statistical Models Susceptibility Gene Techniques Technology Testing Tetracyclines Thyroid Gland Thyroid Nodule Thyroid carcinoma Tissue Microarray Transcript Transgenic Mice Transgenic Model Translating Triage Tumor Cell Invasion Tumor Suppressor Genes Ultrasonography United States Validation Variant Vimentin Western Blotting Work Writing Xenograft Model base bench to bedside cancer cell cancer genetics carcinogenesis cell motility clinical care clinical practice clinically relevant cohort data integration design diagnostic accuracy drug development effective therapy gene interaction genetic linkage analysis genome-wide genome-wide linkage imaging modality improved in vivo in vivo Model inhibitor/antagonist interest meetings member migration mortality mouse model multidisciplinary non-oncogenic novel older patient p21 activated kinase pre-clinical prevent proband programs promoter prospective protein activation protein complex proto-oncogene protein c-ret research study response sodium-iodide symporter therapeutic target thyroid neoplasm tumor tumor growth tumor initiation tumor progression tumorigenesis uptake validation studies

项目摘要

The incidence of thyroid cancer is rising at the second fastest rate of all malignancies in the United States and has an increasing tumor-specific mortality annually, making it an important public health problem. The reasons for this increasing incidence and rising death rate are uncertain. The goal of the P01 application is to address the key issues relating to thyroid cancer predisposition, tumorigenesis, and progression in order to enhance the potential for both early diagnosis and the effective treatment of progressive disease. Based on extensive preliminary data from our group, we propose to: (1) examine and identify predisposing genes for papillary thyroid cancer, (2) determine the critical changes responsible for the development of follicular thyroid cancer in an inherited form of the disease, Cowden syndrome, using a novel animal model, and translate this into a scheme to enhance preoperative diagnosis of this form of thyroid cancer, (3) evaluate and identify the key mechanisms of thyroid cancer induction and dedifferentiation induced by the RET/PTC 1 oncogene, one of the most common genetic abnormalities in papillary thyroid cancer, using a second novel animal model system, and (4) determine key pathways involved in tumor invasion and motility for both follicular and papillary thyroid cancers focusing on the models developed in this P01, and then test novel agents directed at blocking these pathway in vitro and in vivo. Over the past six years, the PI's of the individual projects, and the leaders of the cores have created an environment to successfully perform this integrated P01 that is unique for thyroid cancer. This includes a substantial database, integration with pathology, and a record of successful collaborative genetics, laboratory, drug development, and clinical research as evidenced by approximately thirty co-authored publications. Thus, this P01 represents an integrated Bedside-to-Bench-to-Bedside approach targeting the key clinical issues confronting the diagnosis and management of patients with thyroid cancer.

甲状腺癌的发病率正在以美国所有恶性肿瘤的第二快速率上升，并且每年都有肿瘤特异性的死亡率越来越大，这使其成为重要的公共健康问题。尚不确定发病率和死亡率上升的原因。 P01应用的目的是解决与甲状腺癌倾向，肿瘤发生和进展有关的关键问题，以增强早期诊断和有效治疗进行性疾病的潜力。基于我们小组的广泛初步数据，我们建议：（1）检查并确定乳头状甲状腺癌的易感基因，（2）确定造成卵泡甲状腺癌的发展的关键变化，以疾病的遗传形式，Cowden，Cowden综合征，使用一种新型的动物模型，并将其转化为一种计划，以增强这种形式的甲状腺癌的术前诊断，（3）评估和识别甲状腺癌诱导的关键机制，并由RET/PTC 1癌细胞造成的甲状腺癌诱导和去分化使用第二种新型动物模型系统，以及（4）确定卵泡和乳头状甲状腺癌涉及的关键途径，以及（4）确定涉及肿瘤侵袭和运动型甲状腺癌的关键途径，然后测试旨在在体外和体内阻止这些途径的新型剂。在过去的六年中，各个项目的PI和核心的领导者创造了一个环境，以成功地执行这种对甲状腺癌独有的综合P01。这包括一个大量数据库，与病理学的整合以及成功的合作遗传学，实验室，药物开发和临床研究的记录，大约有30个共同作者的出版物证明了这一点。因此，该P01代表了针对甲状腺癌患者诊断和管理的关键临床问题的综合床头到基础旁边的方法。